Total Payments
$23,230
2024 Payments
$17.51
Companies
4
Transactions
12

Payment Breakdown by Category

Research$23,052 (99.2%)
Food & Beverage$178.64 (0.8%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $23,052 5 99.2%
Food and Beverage $178.64 7 0.8%

Payments by Type

Research
$23,052
5 transactions
General
$178.64
7 transactions

Top Paying Companies

Company Total Records Latest Year
PFIZER INC. $23,069 6 $0 (2024)
Lilly USA, LLC $93.47 3 $0 (2023)
Biohaven Pharmaceutical Holding Company Ltd. $51.63 2 $0 (2022)
Neurelis, Inc. $16.03 1 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $17.51 1 PFIZER INC. ($17.51)
2023 $23,089 6 PFIZER INC. ($23,052)
2022 $108.95 4 Biohaven Pharmaceutical Holding Company Ltd. ($51.63)
2021 $15.31 1 Lilly USA, LLC ($15.31)

All Payment Transactions

12 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
11/15/2024 PFIZER INC. NURTEC ODT (Drug) Food and Beverage In-kind items and services $17.51 General
Category: PAIN
12/07/2023 PFIZER INC. NURTEC ODT (Drug) Cash or cash equivalent $13,500.00 Research
Study: PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN
12/07/2023 PFIZER INC. NURTEC ODT (Drug) Cash or cash equivalent $998.10 Research
Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN
10/05/2023 PFIZER INC. NURTEC ODT (Drug) Cash or cash equivalent $1,439.01 Research
Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN
09/26/2023 PFIZER INC. NURTEC ODT (Drug) Cash or cash equivalent $6,116.58 Research
Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN
06/16/2023 Lilly USA, LLC EMGALITY (Drug), REYVOW Food and Beverage In-kind items and services $36.87 General
Category: Neuroscience
04/06/2023 PFIZER INC. NURTEC ODT (Drug) Cash or cash equivalent $998.10 Research
Study: PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN
11/18/2022 Lilly USA, LLC EMGALITY (Drug), REYVOW Food and Beverage In-kind items and services $41.29 General
Category: Neuroscience
06/11/2022 Biohaven Pharmaceutical Holding Company Ltd. NURTEC ODT (Drug) Food and Beverage Cash or cash equivalent $37.54 General
Category: PRIMARY CARE
06/10/2022 Biohaven Pharmaceutical Holding Company Ltd. NURTEC ODT (Drug) Food and Beverage In-kind items and services $14.09 General
Category: PRIMARY CARE
02/15/2022 Neurelis, Inc. VALTOCO (Drug) Food and Beverage In-kind items and services $16.03 General
Category: EPILEPSY
09/16/2021 Lilly USA, LLC EMGALITY (Drug), REYVOW Food and Beverage In-kind items and services $15.31 General
Category: Neuroscience

Research Studies & Clinical Trials

Study Name Company Amount Records
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE PFIZER INC. $13,500 1
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE PFIZER INC. $9,552 4

About Sara Pavitt

Sara Pavitt is a Student in an Organized Health Care Education/Training Program healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/30/2015. The National Provider Identifier (NPI) number assigned to this provider is 1295120095.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sara Pavitt has received a total of $23,230 in payments from pharmaceutical and medical device companies, with $17.51 received in 2024. These payments were reported across 12 transactions from 4 companies. The most common payment nature is "" ($23,052).

Practice Information

Products in Payments

  • NURTEC ODT (Drug) $23,121
  • EMGALITY (Drug) $93.47
  • VALTOCO (Drug) $16.03

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Austin